Elevated circulating osteoprotegerin and renal dysfunction predict 15-year cardiovascular and all-cause mortality: A prospective study of elderly women

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lewis, Joshua R ^a,b   Lim, Wai H ^a,b   Ueland, Thor ^c   Wong, Germaine ^d   Zhu, Kun ^a,b   Lim, Ee M ^b   Bollerslev, Jens ^c   Prince, Richard L ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; OSTEOPROTEGERIN; BIOLOGICAL MARKER;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PROSPECTIVE STUDY; AUSTRALIA; BLOOD; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; AUSTRALIA; BIOMARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84941702870     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134266     Document Type: Article

References (36)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine. 2004; 351 (13):1296-305. Epub 2004/09/24. doi:10.1056/NEJMoa041031 PMID: 15385656.
2. Lewis JR, Lim W, Dhaliwal SS, Zhu K, Lim EM, Thompson PL, et al. Estimated glomerular filtration rate as an independent predictor of atherosclerotic vascular disease in older women. BMC Nephrol. 2012; 13(1):58. Epub 2012/07/18doi:10.1186/1471-2369-13-58 PMID: 22799523.
3. Lim WH, Lewis JR, Wong G, Dogra GK, Zhu K, Lim EM, et al. Five-year decline in estimated glomerular filtration rate associated with a higher risk of renal disease and atherosclerotic vascular disease clinical events in elderly women. Qjm. 2013; 106(5):443-50. Epub 2013/02/15. doi:10.1093/qjmed/hct043 PMID: 23407347.
4. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. Journal of the American Society of Nephrology: JASN. 2009; 20(12):2625-30. Epub 2009/11/07. ASN.2009050546 [pii] doi:10.1681/ASN.2009050546 PMID: 19892934; PubMed Central PMCID: PMC2794238.
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. Epub 1997/04/18. S0092-8674(00)80209-3 [pii]. PMID: 9108485.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423 (6937):337-42. Epub 2003/05/16. doi:10.1038/nature01658nature01658 [pii]. PMID: 12748652.
7. Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol. 2009; 86(4):933-40. Epub 2009/07/31. jlb.0708419 [pii]doi:10.1189/jlb.0708419PMID: 19641036; PubMed Central PMCID: PMC2752017.
8. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. 2006; 29(7):1664-6. Epub 2006/06/28. 29/7/1664 [pii] doi:10.2337/dc06-0631PMID: 16801598.
9. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106(10):1192-4. Epub 2002/09/05. PMID: 12208791.
10. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. Journal of the American College of Cardiology. 2006; 47(9):1850-7. Epub 2006/05/10. S0735-1097(06)00382-2 [pii] doi:10.1016/j.jacc.2005.12.054PMID: 16682312.
11. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007; 99(4):513-8. Epub 2007/02/13. S0002-9149(06)02158-8 [pii] doi:10.1016/j.amjcard.2006.08.064 PMID: 17293196.
12. Ueland T, Wilson SG, Amirul Islam FM, Mullin B, Devine A, Bollerslev J, et al. A cohort study of the effects of serum OPG and OPG gene polymorphisms on cardiovascular mortality in elderly women. Clinical endocrinology. 2009. Epub 2009/06/11. CEN3605 [pii] doi:10.1111/j.1365-2265.2009.03605.x PMID: 19508593.
13. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2009; 24(10):3157-62doi:10.1093/ndt/gfp253 PMID: 19491380.
14. Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. Journal of the American Society of Nephrology: JASN. 2006; 17(6):1746-54. Epub 2006/05/12. ASN.2005121368 [pii] doi:10.1681/ASN.2005121368 PMID: 16687626.
15. Svensson M, Dahle DO, Mjoen G, Weihrauch G, Scharnagl H, Dobnig H, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2011. Epub 2011/12/17. gfr694 [pii] doi:10.1093/ndt/gfr694 PMID: 22172725.
16. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. Journal of the American College of Cardiology. 2008; 51(6):627-33. Epub 2008/02/12. S0735-1097(07)03676-5 [pii] doi:10.1016/j.jacc.2007.09.058 PMID: 18261681.
17. Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008; 31(6):1163-70. doi:10.1291/hypres.31.1163 PMID: 18716364.
18. Lewis JR, Lim WH, Zhu K, Wong G, Dhaliwal SS, Lim EM, et al. Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study. American journal of nephrology. 2014; 39(1):66-74. Epub 2014/01/25. doi:10.1159/000357787PMID: 24457210.
19. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Archives of internal medicine. 2006; 166(8):869-75. PMID: 16636212.
20. Britt H, Scahill S, Miller G. ICPC PLUS for community health? A feasibility study. Health Inf Manag. 1997; 27(4):171-5. Epub 1997/11/03. PMID: 10178424.
21. Ueland T, Bollerslev J, Wilson SG, Dick IM, Islam FM, Mullin BH, et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone. 2007; 40(1):175-81. PMID: 16949901.
22. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol. 2001; 145(6):685-90. PMID: 11720891.
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. Epub 2009/05/06. 150/9/604 [pii]. PMID: 19414839; PubMed Central PMCID: PMC2763564.
24. World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death: based on the recommendations of the ninth revision conference, 1975, and adopted by the Twenty-ninth World Health Assembly. 1975 revision. ed. Geneva: World Health Organization; 1977. 2v. p.
25. Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, Glasson EJ, et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev. 2008; 32(4):766-77. Epub 2008/11/05. ahr-32-4-766 [pii]. PMID: 18980573.
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003; 289(19):2560-72. doi:10.1001/jama.289.19.2560 PMID: 12748199.
27. World Health Organization. ICD-10: international statistical classification of diseases and related health problems: Tenth revision. 2nd ed. Geneva: World Health Organization; 2004.
28. Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tonnessen T, et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. Journal of internal medicine. 2011; 270 (5):452-60. Epub 2011/06/01. doi:10.1111/j.1365-2796.2011.02393.x PMID: 21623962.
29. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. Journal of the American Society of Nephrology: JASN. 2006; 17(1):262-70. Epub 2005/11/11. ASN.2005030260 [pii] doi:10.1681/ASN.2005030260 PMID: 16280472.
30. Corallini F, Gonelli A, D'Aurizio F, di Iasio MG, Vaccarezza M. Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. Eur J Histochem. 2009; 53(1):19- 24. Epub 2009/04/09. PMID: 19351609.
31. Montanez-Barragan A, Gomez-Barrera I, Sanchez-Nino MD, Ucero AC, Gonzalez-Espinoza L, Ortiz A. Osteoprotegerin and kidney disease. Journal of nephrology. 2014. doi:10.1007/s40620-014-0092-x PMID: 24756971.
32. Morena M, Dupuy AM, Jaussent I, Vernhet H, Gahide G, Klouche K, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2009; 24(11):3389-97. Epub 2009/07/04. gfp301 [pii] doi:10.1093/ndt/gfp301PMID: 19574342.
33. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation. 2008; 117(3):411-20. doi:10.1161/CIRCULATIONAHA.107.707380 PMID: 18172035; PubMed Central PMCID: PMC2680735.
34. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005; 48 (3):561-8. Epub 2005/02/09. doi:10.1007/s00125-004-1652-8 PMID: 15700136.
35. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, et al. Osteoprotegerin levels before and after renal transplantation. American journal of kidney diseases: The official journal of the National Kidney Foundation. 2001; 38(4 Suppl 1):S175-7. Epub 2001/09/29. PMID: 11576949.
36. Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damas JK, et al. Systemic inflammatory markers in COPD: Results from the Bergen COPD Cohort Study. Eur Respir J. 2010; 35(3):540-8. Epub 2009/08/01. doi:10.1183/09031936.00088209 PMID: 19643942.